Fran E. Cook-Bolden, MD, a top-ranked, board-certified dermatologist and cosmetic surgeon is dedicated to providing high-quality, individualized care. She treats patients throughout the tristate area, across the US and internationally at offices in New York.
She is the Founding Associate Director of the Skin of Color Center and currently is a clinical assistant professor of Dermatology at Mount Sinai Health Systems and Director of Skin Specialty Dermatology and the Ethnic Skin Specialty Group where Dr. Cook-Bolden conducts cutting-edge clinical investigations as Principal Investigator directing a highly qualified research team on a wide range of skin, hair and scalp concerns and the use of lasers and other devices in all skin types.
A member of the American Academy of Dermatology, past Board of Directors of the Women’s Dermatologic Society and past Executive Board member of the Greater New York Dermatology Society, Dr. Cook-Bolden is also a member of the American Society of Dermatologic Surgery, American Society for Laser Medicine and Surgery, National Medical Association, and several other organizations. She serves on many advisory boards and as a consultant for the pharmaceutical, laser, and beauty industry, in addition to being a speaker/lecturer
across the United States and abroad for these industries and at medical centers and universities across the country, recently launching new products in Dubai, Greece and Barcelona.
Widely published in medical and lay publications, she is the co-author of Beautiful Skin of Color: A Comprehensive guide to Asian, Olive and Dark Skin. She has been a guest on numerous local and national radio and television news broadcasts and internet media to address a broad range of skin health and beauty concerns including CNN, the Today Show, CBS Morning Show, ABC News Now, Good Day New York, PBS, the Dr. Oz show, BET Centric’s Culture List, Sirius Satellite radio–Martha Stewart show, The Discovery Channel.com. She has been honored as a Castle Connolly Top Doctors, New York and a New York Times Super Doctor for many years and was recently selected for the 2017 Exceptional Women in Medicine award by Castle Connolly.
Dr. Cook-Bolden offers patients a full spectrum of care, including medical dermatology for all ages, skin cancer screenings and treatment, and dermatologic surgery, as well as cosmetic and antiaging treatments including Botox®, cosmetic fillers, hair removal laser, laser resurfacing, hair rejuvenation and growth, nonsurgical fat reduction and noninvasive “lifting” procedures with the state-of-the-art Ultherapy® system. She is the co-developer of Trufora, a clinically proven, science-based, anti-aging skincare line. Now featured on HSN as “Best in Beauty”, Trufora products contain ingredients that are pharmaceutical grade, vegan, crueltyfree, organic, preservative free or using natural preservatives.
|Biochemistry (magna cum laude), Dillard University, New Orleans, LA|
|Howard University, College of Medicine, Washington, DC|
|State University of New York Health Science Center at Brooklyn, NY New York Medical College, Valhalla, NY, Dermatology Residency|
Novel Tretinoin 0.05% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Hispanic PopulationCook-Bolden, F. E., Weinkle, S. H., Guenin, E., Bhatt, V.Journal of drugs in dermatology : JDD 2019 Jan 27
Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.Green, L. J., Green, L. J., Green, L. J., Kerdel, F. A , Kerdel, F. A , Kerdel, F. A., Cook-Bolden, F. E., Cook-Bolden, F. E., Cook-Bolden, F. E., Bagel, J., Bagel, J., Bagel, J., Lin, T., Lin, T., Lin, T., Martin, G., Martin, G., Martin, G., Pillai, R., Pillai, R., Pillai, R., Israel, R., Israel, R., Israel, R., Ramakrishna, T., Ramakrishna, T., Ramakrishna, T.Journal of drugs in dermatology : JDD 2018 Oct 27
Efficacy, Safety, and Tolerability of Topical Dapsone Gel, 7.5% for Treatment of Acne Vulgaris by Fitzpatrick Skin Phototype.Taylor, S. C., Cook-Bolden, F. E., McMichael, A., Downie, J. B., Rodriguez, D. A., Alexis, A. F., Callender, V. D., Alvandi, N.Journal of drugs in dermatology: JDD 2018 Feb 21
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial. Kircik, L. H., DuBois, J., Draelos, Z. D., Werschler, P., Grande, K., Cook Bolden, F. E., Weng, E., Berk, D. R., Ahluwalia, G.Journal of drugs in dermatology: JOO 2018 Jan 11
Adapalene/Benzoyl Peroxide Gel 0.3%/2.5%: A Safe and Effective Acne Therapy in All Skin Phototypes.Alexis, A. F., Alexis, A. F., Cook-Bolden, F. E., Cook-Bolden, F. E., York, J. P., York, J. P.Journal of drugs in dermatology: JOO 2017 Jul 8
Efinaconazole solution 10% for treatment of toenail onychomycosis in Latino patients.Cook-Bolden , F. E., Cook-Bolden , F. E., Lin, T., Lin, T.Cutis 2017 May 12 1
Emerging Issues in Adult Female Acne.Zeichner, J. A., Zeichner, J. A., Zeichner, J. A., Baldwin, H. E., Baldwin, H. E., Baldwin, H. E., Cook-Bolden, F. E., Cook-Bolden, F. E., Cook-Bolden, F. E., Eichenfield, L. F., Eichenfield, L. F., Eichenfield, L. F., Fallon Friedlander, S., Fallon-Friedlander , S., Fallon-Friedlander, S., Rodriguez, D. A., Rodriguez, D. A., Rodriguez, D. A.The Journal of clinical and aesthetic dermatology 2017Feb18
Results of a Phase 2, Randomized,Vehicle-Controlled Study Evaluating the Efficacy,Tolerability, and Safety of Daily or Twice Daily SB204 for the Treatment of Acne Vulgaris.Eichenfield, L. F., Gold, L. S., Nahm, W. K., Cook-Bolden, F. E., Pariser, D. M.Journal of drugs in dermatology: JOO 2017 Jan 18
Efficacy, Safety, and Dermal Tolerability of Dapsone Gel, 7.5% in Patients with Moderate Acne Vulgaris: A Pooled Analysis of Two Phase 3 Trials.Thiboutot, D. M., Kircik, L., McMichael, A., Cook-Bolden, F. E., Tyring, S. K., Berk, D. R., Chang-Lin, J. E., Lin, V., Kaoukhov, A.The Journal of clinical and aesthetic dermatology 2016 Nov 17
[Not Available].Hougeir, F. G., Cook-Bolden , F. E., Rodriguez, D., Berlin, J. M.The Journal of clinical and aesthetic dermatology 2015 Jun 6
COOK-BOLDEN, FE (con’t)
Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris.Cook-Bolden, F. E.The Journal of clinical and aesthetic dermatology 2015 Jun 2
An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris.Pariser, D. M., Rich, P., Cook-Bolden, F. E., Korotzer, A.Journal of drugs in dermatology : JOO 2014 Sep 17 1
A novel 0.65 millisecond pulsed 1064 nm laser to treat skin of color without skin cooling or anesthetics.Cook-Bolden, F.Joumal of drugs in dermatology : JDD 2012 May 15 3
Treatment of moderate to severe acne vulgaris in a Hispanic population: a post-hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel.Cook-Bolden, F. E.J Drugs Dermatol 2012 Mar 29 10
Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial.Sofen, H., Hudson, C. P., Cook-Bolden , F. E., Preston, N., ColA3 n, L. E., ColA3 n, L. E., Caveney, S. W., Gottschalk, R. W.Journal of drugs in dermatology: JOO 2011 Aug 6 23
Topically applied physiologically balanced growth factors: a new paradigm of skin rejuvenation.Sundaram, H., Mehta, R.C., Norine, J.A., Kircik, L., Cook-Bolden, F.E., Atkin, D.H., Werschler, P.W., Fitzpatrick, R.E.J Drugs Dermatol 2009-05-01 11
Clinical presentation and diagnosis of acne: patient-centric considerations.Cook-Bolden, F. E.Cutis 2008 Oct 18 10
An open-label study of the efficacy and tolerability of microencapsulated hydroquinone 4% and retinal 0.15% with antioxidants for the treatment of hyperpigmentation.Cook Bolden, F. E., Hamilton, S. F.Cutis 2008 May 22
Twice-daily applications of benzoyl peroxide 5%/clindamycin 1% gel versus vehicle in the treatment of pseudofolliculitis barbae.Cook-Bolden, F. E., Barba , A , Halder, R., Taylor , S.Cutis 2004 Jul 2 54
Defining pseudofolliculitis barbae in 2001: a review of the literature and current trends.Perry, P. K., Perry, P. K., Cook-Bolden, F. E., Cook-Bolden, F. E., Rahman, Z., Rahman, Z., Jones , E., Jones , E., Taylor, S. C. , Taylor, S. C.Journal of the American Academy of Dermatology 2002 Jan 25 10
Identification of a recurrent mutation in keratin 6a in a patient with overlapping clinical features of pachyonychia congenita types 1 and 2.Ward, K. M., Cook-Bolden, F. E., Christiano, A M., Celebi, J. T.Clin Exp Dermatol 2003 Jul 10
Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis.Hebert, A A , Cook-Bolden, F. E., Basu, S., Calvarese , B., Trancik, R. J.J Drugs Dermatol 2007 Feb 5
Subject preferences for acne treatments containing adapalene gel 0.1%: results of the MORE trial.Cook-Bolden, F.Cutis 2006 Jul 27
Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature.Drehs, M. M., Cook-Bolden, F., Tanzi, E. L., Weinberg, J. M.Dermatol Surg 2002 May 16
Defining skin of color.Taylor, S. C., Cook-Bolden, F.Cutis 2002 Jun 34
Topical imiquimod 5% cream in the treatment of Bowen’s disease of the penis.Cook Bolden, F., Weinberg, J. M.J Am Acad Dermatol 2002 Jan
Keloidal scars: a review with a critical look at therapeutic options.Shaffer, J. J., Taylor,
S. C., Cook-Bolden , F.J Am Acad Dermatol 2002 Feb 84
Acne vulgaris in skin of color.Taylor, S. C., Cook-Bolden, F., Rahman, Z., Strachan, D.J Am Acad Dermatol 2002 Feb 13
Phase 4 study to assess tretinoin pump for the treatment of facial acne.Eichenfield, L. F., Nighland, M., Rossi, A. B., Cook-Bolden, F., Grimes, P., Fried, R., Levy, S.J Drugs Dermatol 2008 Dec 01